Aurora Cannabis Announces Fiscal 2027 Second Quarter Results
Aurora Cannabis reported Q2 2027 net revenue of $86.0M, including record international medical cannabis revenue of $86.0M, up 44% YoY. Adjusted EBITDA was $13.997M, with free cash flow outflow improving by $14.0M. The company has $133.0M in cash and no debt. Aurora will be acquired by Organigram, with a shareholder meeting expected in December 2026.
How this was made
The 30-second read
Why it matters
The acquisition announcement is the primary new fact, likely moving Aurora's stock sharply.
Market read
A major M&A deal in the cannabis industry with immediate price impact for the target.
What to watch
Financing terms and post‑closing integration risks may limit upside.
Background
Aurora Cannabis reported FY2027 Q2 results and simultaneously disclosed a definitive acquisition agreement with Organigram.
Ticker impact
Organigram announced a definitive agreement to acquire all outstanding Aurora Cannabis shares.
upside pressure as investors price in the acquisition premium
The deal represents a full‑company takeover with a cash/stock consideration, which historically drives target‑stock rallies.
Market effects
Consolidation in the cannabis sector may pressure peers' valuations.
Canadian cannabis market sees potential shift in competitive dynamics.
Highlights continued M&A activity in regulated growth industries.
Counterpoint
Deal could face regulatory hurdles, causing a pull‑back in Aurora's price.
Key entities
- CompanyAurora Cannabis
Target of the acquisition, listed on NASDAQ/TSX under ACB.
- CompanyOrganigram Global Inc.
Acquirer, entering a definitive agreement to purchase Aurora.
